6.43
+6.28%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Laekna
Its shares trade on HKEX under the ticker 2105.HK. It has been listed since 29 June 2023. In the fiscal year to 31 December 2025, it reported revenue of CN¥106.7m and a net loss of CN¥229.3m. At that date it held total assets of CN¥1.41bn and shareholders' equity of CN¥1.18bn.
Laekna, Inc. engages in the clinical stage research and development of biopharmaceutical products. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2023-06-29. The firm is mainly engaged in the research and development of drug candidates for monotherapy and combination therapy, focusing on the treatment of various cancers and liver fibrosis diseases. The firm's main product pipelines include LAE002 and LAE001. The LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors. The LAE001 is an androgen synthesis inhibitor that simultaneously inhibits cytochrome P450 family 17 subfamily A member 1 (CYP17A1) and cytochrome P450 family 11 subfamily B member 2 (CYP11B2) for the treatment of prostate cancer. The firm mainly conducts its businesses in China, the United States, Europe and South Korea.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 29 Jun 2023
- Employees
- 93
- Website
- laekna.com ↗
Leadership
Pay as last reported
- Dr. Xiangyang LuExecutive Chairman of the Board, Chief Executive Officer, since 2016CN¥2.1m
- Mr. Kwok Keung ChauChief Financial Officer, Executive Director
- Ms. Ling XieSenior Vice President, Executive Director, since 2017CN¥5.8m
- Dr. Xiang-Ju GuChief Scientific Officer, Executive Director, since 2020CN¥4.4m
- Ms. Liqing WangVice President
- Dr. Yong YueChief Medical Officer
- Ms. Wing Nga HoJoint Company Secretary
- Mr. Chenyu KeJoint Company Secretary
- Mr. Yuan SunNon-Executive Director
- Dr. Guowei WangNon-Executive Director
- Dr. Min LiIndependent Non-Executive Director
- Dr. Xudong YinIndependent Non-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Laekna Inc focuses on clinical stage biopharmaceutical R&D with 93 employees in Shanghai.
- LAE002 targets ovarian cancer and PD-1/PD-L1 resistant tumors in the Health Care sector.
- LAE001 inhibits CYP17A1 and CYP11B2 for prostate cancer treatment in China and the US.
Weaknesses
- Laekna's IPO in June 2023 shows limited market presence in Europe and South Korea.
- The company has only two product pipelines LAE002 and LAE001 for cancer treatments.
- Laekna employs 93 full-time staff in Shanghai with no global expansion plans.
Opportunities
- Expansion into South Korea for LAE002 and LAE001 cancer treatments.
- Growing demand for cancer therapies in the United States and Europe.
- New partnerships in the Health Care sector for biopharmaceutical R&D.
Threats
- Competition from established biotech firms in the Health Care industry.
- Regulatory challenges in the United States and Europe for new drug approvals.
- Lack of product diversity beyond cancer treatments in the Health Care sector.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.